JP2025506001A5 - - Google Patents
Info
- Publication number
- JP2025506001A5 JP2025506001A5 JP2024546261A JP2024546261A JP2025506001A5 JP 2025506001 A5 JP2025506001 A5 JP 2025506001A5 JP 2024546261 A JP2024546261 A JP 2024546261A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2025506001 A5 JP2025506001 A5 JP 2025506001A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- chelating agent
- salt
- mbq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263308211P | 2022-02-09 | 2022-02-09 | |
| US63/308,211 | 2022-02-09 | ||
| PCT/IB2023/051159 WO2023152671A1 (en) | 2022-02-09 | 2023-02-09 | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506001A JP2025506001A (ja) | 2025-03-05 |
| JP2025506001A5 true JP2025506001A5 (https=) | 2026-02-06 |
Family
ID=85328574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024546261A Pending JP2025506001A (ja) | 2022-02-09 | 2023-02-09 | ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250161502A1 (https=) |
| EP (1) | EP4475900A1 (https=) |
| JP (1) | JP2025506001A (https=) |
| CN (1) | CN118647415A (https=) |
| WO (1) | WO2023152671A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121793988A (zh) | 2023-09-13 | 2026-04-03 | 东丽株式会社 | 癌的治疗、预防和/或诊断用药物组合物 |
| WO2025218879A1 (en) * | 2024-04-15 | 2025-10-23 | Itm Technologies Munich Se | Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same |
| WO2025255396A1 (en) * | 2024-06-05 | 2025-12-11 | Ariceum Therapeutics Gmbh | Radiopharmaceutical composition and methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004273775C1 (en) * | 2003-03-25 | 2010-03-04 | Sloan-Kettering Institute For Cancer Research | Methods for protection from toxicity of alpha emitting elements during radioimmunotherapy |
| RS65188B1 (sr) | 2016-03-22 | 2024-03-29 | Univ Johns Hopkins | Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate |
| CN111032632B (zh) * | 2017-05-30 | 2024-04-12 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| JP7801207B2 (ja) | 2019-07-08 | 2026-01-16 | ３ベー ファーマシューティカルズ ゲーエムベーハー | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
| FI3997103T3 (fi) | 2019-07-08 | 2025-02-03 | 3B Pharmaceuticals Gmbh | Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö |
| EP4178982A1 (en) * | 2020-07-13 | 2023-05-17 | Precirix N.V. | Antibody fragment against folr1 |
| IL303925A (en) | 2021-01-07 | 2023-08-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4122499A1 (en) | 2021-07-23 | 2023-01-25 | 3B Pharmaceuticals GmbH | Fibroblast activation protein inhibitors and use thereof |
-
2023
- 2023-02-09 EP EP23706856.4A patent/EP4475900A1/en active Pending
- 2023-02-09 WO PCT/IB2023/051159 patent/WO2023152671A1/en not_active Ceased
- 2023-02-09 US US18/836,576 patent/US20250161502A1/en active Pending
- 2023-02-09 CN CN202380018997.0A patent/CN118647415A/zh active Pending
- 2023-02-09 JP JP2024546261A patent/JP2025506001A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025506001A5 (https=) | ||
| Van Laere et al. | Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside | |
| JP2025183243A (ja) | 安定な濃厚放射性核種錯体溶液 | |
| JP2023552180A5 (https=) | ||
| JP2025111424A5 (https=) | ||
| US20090155167A1 (en) | Automated method | |
| KR20210086637A (ko) | 방사성핵종 착물의 합성 방법 | |
| JP2023117417A5 (https=) | ||
| Grieve et al. | The evolving coordination chemistry of radiometals for targeted alpha therapy | |
| US20250127940A1 (en) | Radiopharmaceutical and methods | |
| Le Fur et al. | Pyclen tri-n-butylphosphonate ester as potential chelator for targeted radiotherapy: from yttrium (III) complexation to 90Y radiolabeling | |
| AU2024227297A1 (en) | Methods for radiolabeling PSMA binding ligands and their kits | |
| Matazova et al. | Insights into actinium complexes with tetraacetates─ AcBATA versus AcDOTA: thermodynamic, structural, and labeling properties | |
| JP2025506322A (ja) | 放射性核種錯体の大規模合成のための方法 | |
| US20250145664A1 (en) | Pharmaceutical compositions for imaging, diagnosis and treatment of cancer | |
| Holland | The radiochemistry of zirconium | |
| WO2026025213A1 (zh) | 一种含rgd多肽的组合物及其应用 | |
| RU2859685C2 (ru) | Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC | |
| Pandey et al. | Advances in Targeted Radiopharmaceuticals: Challenges and Opportunities | |
| Srivastava et al. | Targeted Radiopharmaceuticals and Imaging: Development Challenges and Opportunities | |
| WO2025030160A1 (en) | Chelating compounds and methods of uses thereof | |
| AU2023227218A1 (en) | Radiopharmaceutical and methods | |
| Notation | Radioactivity, Radionuclides, and Radiopharmaceuticals | |
| Test | Asian Journal of Medical Radiological Research Original Article |